Literature DB >> 1359289

Ondansetron and hyperemesis gravidarum.

E Guikontes, A Spantideas, J Diakakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1359289     DOI： 10.1016/0140-6736(92)92923-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy.

Authors:  P Mazzotta; L A Magee
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).

Authors:  D G Tincello; M J Johnstone
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

Review 3.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  Placental transfer of ondansetron during early human pregnancy.

Authors:  Shing-Shun N Siu; Matthew T V Chan; Tze-Kin Lau
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Treatment of nausea and vomiting in pregnancy. When should it be treated and what can be safely taken?

Authors:  C Nelson-Piercy
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 6.  Ondansetron and pregnancy: Understanding the data.

Authors:  Debra Kennedy
Journal:  Obstet Med       Date:  2015-12-23

Review 7.  Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome.

Authors:  Gabrielle L McLemore; Tamorah Lewis; Catherine H Jones; Estelle B Gauda
Journal:  Semin Fetal Neonatal Med       Date:  2012-10-09       Impact factor: 3.926

8.  Off-label use of ondansetron in pregnancy in Western Australia.

Authors:  Lyn Colvin; Andrew W Gill; Linda Slack-Smith; Fiona J Stanley; Carol Bower
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.